IP Library Granted Patent US 7,524,661
Granted Patent B2
US 7,524,661 · App. 11/346,146 · Granted Apr 28, 2009

Preparation of a therapeutic composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,661
App. No.
11/346,146
Granted
Apr 28, 2009
Kind
B2
Abstract

Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 nm/280 nm and 1.359 at 260 nm/230 nm.

Claims (16)

1. A method for producing a therapeutic composition comprising the steps of:

a) suspending about 35.0 grams of casein, about 17.1 grams of beef peptone, about 22.0 grams ribonucleic acid (RNA), and about 3.25 grams of bovine serum albumin in about 2.5 liters of water;

b) adding about 16.5 grams of sodium hydroxide to the mixture from step a;

c) autoclaving the product from step b at about 9 lbs pressure and 200-230° F. until the RNA is completely digested;

d) cooling the product from step c to about 3-8° C.;

e) sequentially filtering the product from step d through a 2 micron filter, a 0.45 micron filter and a 0.2 micron filter;

f) diluting the product from step e with water to yield a final volume of about 5 liters;

g) adjusting the pH of the product from step f to a range of about 7.3 to 7.6;

h) filtering the product from step g through a second 0.2 micron filter; and

i) autoclaving the product from step h at 240° F. and 20-30 pounds pressure for about 30 minutes;

whereby the therapeutic composition comprises components having molecular weights less than 14 KDa.

2. The method of claim 1 , wherein the RNA is yeast RNA.

3. The method of claim 1 , wherein step e is repeated.

4. A product produced by the method of claim 1 .

5. A product produced by the method of claim 2 or 3 .

6. A pharmaceutical composition comprising a) the product of claim 4 ; and b) a pharmaceutically acceptable carrier.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2013
From: FRIEDLAND, BERNARD
To: ADVANCED VIRAL RESEARCH CORP.
Reel/Frame 029694/0825 →
MERGER Recorded Jan 25, 2013
From: BBM HOLDINGS, INC.
To: OHR PHARMACEUTICAL, INC.
Reel/Frame 029695/0403 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 022542 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE OWNERSHIP TRANSFERED FROM ADVANCED VIRAL RESEARCH CORP. AND TRIAD BIOTHERAPEUTICS, INC. TO BBM HOLDINGS, INC. Recorded Jan 25, 2013
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: BBM HOLDINGS, INC.
Reel/Frame 029700/0726 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR/ASSIGNEE NAMES PREVIOUSLY RECORDED ON REEL 022510 FRAME 0187. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNORS ARE ADVANCED VIRAL RESEARCH CORP. AND TRIAD BIOTHERAPEUTICS, INC., AND THE ASSIGNEE IS YA GLOBAL INVESTMENTS, L.P. Recorded Apr 14, 2009
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: YA GLOBAL INVESTMENTS, L.P. (F/K/A CORNELL CAPITAL PARTNERS, L.P.)
Reel/Frame 022542/0001 →
FORECLOSURE BY THIRD PARTY Recorded Apr 6, 2009
From: YA GLOBAL INVESTMENTS, L.P. (F/K/A CORNELL CAPITAL PARTNERS, L.P.)
To: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
Reel/Frame 022510/0187 →